# Biotech/Pharma Companies - PubMed Full-Text Search API Leads

**Target Market:** Companies using AI/ML that would benefit from comprehensive PubMed full-text search capabilities.

**Last Updated:** February 2026

---

## Summary

This document contains 65+ biotech and pharma companies that are prime candidates for a PubMed full-text search API. These companies use AI/ML for drug discovery, diagnostics, clinical research, and health tech—all areas where access to comprehensive scientific literature is critical.

---

## Category 1: AI Drug Discovery Platforms

These companies build AI models that need to ingest and understand scientific literature to discover new drugs.

### 1. Insilico Medicine
- **What they do:** End-to-end AI drug discovery using Pharma.AI platform for target discovery, molecule generation, and clinical trial prediction
- **Location:** Cambridge, MA / Hong Kong
- **Why they'd want PubMed full-text:** Train AI models on biomedical literature, validate drug targets, understand disease mechanisms
- **Website:** https://insilico.com
- **LinkedIn:** https://linkedin.com/company/insilico-medicine

### 2. Recursion Pharmaceuticals
- **What they do:** Maps biology using AI, automation, and massive biological datasets; acquired Exscientia
- **Location:** Salt Lake City, UT
- **Why they'd want PubMed full-text:** Literature mining for target validation, mechanism of action research, competitive intelligence
- **Website:** https://recursion.com
- **Contact:** info@recursion.com
- **LinkedIn:** https://linkedin.com/company/recursion-pharmaceuticals

### 3. Atomwise
- **What they do:** Structure-based deep learning drug discovery with AtomNet platform; 3+ trillion compound library
- **Location:** San Francisco, CA
- **Why they'd want PubMed full-text:** Literature-based target identification, understanding protein structures from publications
- **Website:** https://atomwise.com
- **Contact:** info@atomwise.com
- **LinkedIn:** https://linkedin.com/company/atomwise

### 4. Generate Biomedicines
- **What they do:** Generative biology platform for novel protein therapeutics; $1B+ Novartis partnership
- **Location:** Cambridge, MA
- **Why they'd want PubMed full-text:** Protein structure research, understanding therapeutic targets from literature
- **Website:** https://generatebiomedicines.com
- **LinkedIn:** https://linkedin.com/company/generate-biomedicines

### 5. Isomorphic Labs
- **What they do:** DeepMind spinoff using AlphaFold for AI drug design; led by Nobel laureate Demis Hassabis
- **Location:** London, UK
- **Why they'd want PubMed full-text:** Protein structure validation, target discovery, mechanism research
- **Website:** https://isomorphiclabs.com

### 6. BenevolentAI
- **What they do:** Knowledge Graph connecting genes, diseases, and compounds for drug discovery
- **Location:** London, UK
- **Why they'd want PubMed full-text:** Build and expand biomedical knowledge graphs from literature
- **Website:** https://benevolent.com
- **Contact:** info@benevolent.com
- **LinkedIn:** https://linkedin.com/company/benevolentai

### 7. Schrödinger
- **What they do:** Physics-based computational chemistry + machine learning for drug design
- **Location:** New York, NY
- **Why they'd want PubMed full-text:** Computational chemistry validation, molecular modeling research
- **Website:** https://schrodinger.com
- **LinkedIn:** https://linkedin.com/company/schr-dinger

### 8. insitro
- **What they do:** Machine learning platform integrating human genetics for drug discovery; Lilly partnership
- **Location:** San Francisco, CA
- **Why they'd want PubMed full-text:** Genetic research literature, disease mechanism studies
- **Website:** https://insitro.com

### 9. Relay Therapeutics
- **What they do:** Protein motion modeling with Dynamo platform for precision oncology
- **Location:** Cambridge, MA
- **Why they'd want PubMed full-text:** Protein dynamics research, cancer biology literature
- **Website:** https://relaytx.com
- **LinkedIn:** https://linkedin.com/company/relay-therapeutics

### 10. Nimbus Therapeutics
- **What they do:** AI-enabled structure-based drug design; $6B Takeda deal for TYK2 inhibitor
- **Location:** Cambridge, MA
- **Why they'd want PubMed full-text:** Target validation from literature, competitive landscape analysis
- **Website:** https://nimbustx.com

### 11. Iktos
- **What they do:** Generative AI (Makya) + retrosynthesis AI (Spaya) for small molecule discovery
- **Location:** Paris, France
- **Why they'd want PubMed full-text:** Chemical synthesis routes, medicinal chemistry literature
- **Website:** https://iktos.ai

### 12. Anima Biotech
- **What they do:** mRNA biology modulators using Lightning.AI platform; AbbVie, Eli Lilly partnerships
- **Location:** New Jersey, USA
- **Why they'd want PubMed full-text:** mRNA biology research, target pathway literature
- **Website:** https://animabiotech.com

### 13. BPGbio
- **What they do:** NAi Interrogative Biology platform with 100,000+ patient biobank samples
- **Location:** Cambridge, MA
- **Why they'd want PubMed full-text:** Patient biomarker validation, translational research literature
- **Website:** https://bpgbio.com

### 14. Model Medicines
- **What they do:** GALILEO platform for 3D protein structure analysis; 192 compounds targeting 26 targets
- **Location:** USA
- **Why they'd want PubMed full-text:** Structural biology papers, antiviral research
- **Website:** https://modelmedicines.com

### 15. Cradle Bio
- **What they do:** Generative AI for protein engineering; Novo Nordisk, J&J partnerships
- **Location:** Delft, Netherlands
- **Why they'd want PubMed full-text:** Protein engineering literature, enzyme optimization research
- **Website:** https://cradle.bio
- **LinkedIn:** https://linkedin.com/company/cradle-bio

### 16. Antiverse
- **What they do:** AI-designed antibodies for rare diseases and immuno-oncology
- **Location:** Cardiff, UK
- **Why they'd want PubMed full-text:** Antibody engineering literature, immunology research
- **Website:** https://antiverse.io

### 17. XtalPi
- **What they do:** AI + quantum mechanics for molecular property prediction (ID4 platform)
- **Location:** Shenzhen, China / Cambridge, MA
- **Why they'd want PubMed full-text:** Crystallography literature, ADMET property research
- **Website:** https://xtalpi.com

### 18. CHARM Therapeutics
- **What they do:** DragonFold platform for 3D deep learning drug design in oncology
- **Location:** London, UK
- **Why they'd want PubMed full-text:** Protein-ligand interaction literature, oncology research
- **Website:** https://charmtx.com

### 19. Enveda Biosciences
- **What they do:** AI + mass spectrometry to discover drugs from natural products
- **Location:** Boulder, CO
- **Why they'd want PubMed full-text:** Natural products literature, phytochemistry research
- **Website:** https://envedabio.com

### 20. Reverie Labs
- **What they do:** AI-powered small molecule design for precision oncology
- **Location:** Cambridge, MA
- **Why they'd want PubMed full-text:** Cancer pathway literature, medicinal chemistry
- **Website:** https://reverielabs.com

---

## Category 2: Precision Medicine & Diagnostics

Companies using AI for diagnostics and personalized medicine need literature for biomarker discovery.

### 21. Tempus
- **What they do:** Real-world clinical + molecular data for personalized cancer care
- **Location:** Chicago, IL
- **Why they'd want PubMed full-text:** Biomarker validation, clinical outcomes literature
- **Website:** https://tempus.com

### 22. Guardant Health
- **What they do:** Precision oncology with liquid biopsy and ctDNA monitoring; 26 AI patents
- **Location:** Redwood City, CA
- **Why they'd want PubMed full-text:** Cancer genomics literature, biomarker research
- **Website:** https://guardanthealth.com
- **LinkedIn:** https://linkedin.com/company/guardanthealth

### 23. PathAI
- **What they do:** AI-powered pathology diagnostics for oncology biomarkers
- **Location:** Boston, MA
- **Why they'd want PubMed full-text:** Pathology literature, histological biomarker validation
- **Website:** https://pathai.com
- **Contact:** cs@pathai.com
- **LinkedIn:** https://linkedin.com/company/pathai

### 24. Nucleai
- **What they do:** Spatial biology AI platform for drug development and patient outcomes
- **Location:** Chicago, IL
- **Why they'd want PubMed full-text:** Spatial biology literature, tumor microenvironment research
- **Website:** https://nucleai.ai
- **LinkedIn:** https://linkedin.com/company/nucleai-ai

### 25. PathomIQ
- **What they do:** AI biomarker discovery for cancer diagnosis
- **Location:** Cupertino, CA
- **Why they'd want PubMed full-text:** Cancer biomarker literature, diagnostic validation
- **Website:** https://pathomiq.com
- **LinkedIn:** https://linkedin.com/company/pathomiq

### 26. Gritstone Bio
- **What they do:** Neoantigen-based immunotherapies; #1 in pharma AI patents (33 since 2020)
- **Location:** Emeryville, CA
- **Why they'd want PubMed full-text:** Immunotherapy literature, neoantigen discovery research
- **Website:** https://gritstoneoncology.com

### 27. Owkin
- **What they do:** Federated learning for precision medicine; $180M Sanofi partnership
- **Location:** Paris, France / New York
- **Why they'd want PubMed full-text:** Clinical outcomes literature, multimodal data research
- **Website:** https://owkin.com
- **LinkedIn:** https://linkedin.com/company/owkin

### 28. Berkeley Lights
- **What they do:** Beacon platform for cellular analytics in antibody/cell therapy discovery
- **Location:** Emeryville, CA
- **Why they'd want PubMed full-text:** Cell biology literature, biologics research
- **Website:** https://berkeleylights.com

### 29. Ardigen
- **What they do:** ImmunoMind platform for neoantigen identification in immuno-oncology
- **Location:** Kraków, Poland
- **Why they'd want PubMed full-text:** Immunogenomics literature, cancer vaccine research
- **Website:** https://ardigen.com
- **Contact:** hello@ardigen.com
- **LinkedIn:** https://linkedin.com/company/ardigen-s-a

### 30. Genialis
- **What they do:** AI-driven biomarker discovery for immuno-oncology and CNS disorders
- **Location:** Singapore
- **Why they'd want PubMed full-text:** Biomarker validation, gene expression literature
- **Website:** https://genialis.com

---

## Category 3: Clinical Trial AI

Companies optimizing clinical trials need literature for trial design and patient matching.

### 31. Unlearn.AI
- **What they do:** Digital twins of clinical trial participants for trial optimization
- **Location:** San Francisco, CA
- **Why they'd want PubMed full-text:** Clinical trial literature, patient outcome prediction research
- **Website:** https://unlearn.ai
- **LinkedIn:** https://linkedin.com/company/unlearn-ai

### 32. Medidata (Dassault Systèmes)
- **What they do:** AI clinical trial platform for trial design and execution
- **Location:** New York, NY
- **Why they'd want PubMed full-text:** Trial protocol literature, regulatory precedent research
- **Website:** https://medidata.com

### 33. IQVIA
- **What they do:** Clinical research and healthcare analytics with AI
- **Location:** Durham, NC
- **Why they'd want PubMed full-text:** Clinical research literature, real-world evidence
- **Website:** https://iqvia.com

### 34. ConcertAI
- **What they do:** Oncology real-world evidence and AI SaaS for clinical research
- **Location:** Cambridge, MA
- **Why they'd want PubMed full-text:** Oncology literature, treatment outcome research
- **Website:** https://concertai.com

### 35. Saama
- **What they do:** Life sciences analytics with AI for clinical development
- **Location:** Campbell, CA
- **Why they'd want PubMed full-text:** Clinical development literature, safety signal detection
- **Website:** https://saama.com

### 36. Deep6.ai
- **What they do:** AI for clinical trial patient recruitment and matching
- **Location:** Pasadena, CA
- **Why they'd want PubMed full-text:** Eligibility criteria literature, patient population research
- **Website:** https://deep6.ai

### 37. BullFrog AI
- **What they do:** AI platform for clinical development decision support
- **Location:** Boyds, MD
- **Why they'd want PubMed full-text:** Drug development literature, regulatory pathway research
- **Website:** https://bullfrogai.com
- **LinkedIn:** https://linkedin.com/company/bullfrogai

### 38. HopeAI
- **What they do:** AI-powered clinical evidence for drug development
- **Location:** Princeton, NJ
- **Why they'd want PubMed full-text:** Clinical evidence synthesis, regulatory literature
- **Website:** https://hopeai.co
- **LinkedIn:** https://linkedin.com/company/hopeai-co

---

## Category 4: Genomics & RNA Therapeutics

Companies in genetic medicine need comprehensive literature access.

### 39. Deep Genomics
- **What they do:** AI for RNA therapeutics targeting genetic disorders (SPIDEX platform)
- **Location:** Toronto, Canada
- **Why they'd want PubMed full-text:** Genetic disorder literature, RNA biology research
- **Website:** https://deepgenomics.com
- **Contact:** press@deepgenomics.com
- **LinkedIn:** https://linkedin.com/company/deep-genomics

### 40. Verge Genomics
- **What they do:** AI analysis of genomic/transcriptomic data for ALS, Parkinson's
- **Location:** South San Francisco, CA
- **Why they'd want PubMed full-text:** Neurodegeneration literature, genetic target validation
- **Website:** https://vergegenomics.com
- **LinkedIn:** https://linkedin.com/company/verge-genomics

### 41. GenBio AI
- **What they do:** AI-Driven Digital Organism (AIDO) simulating DNA, RNA, proteins at scale
- **Location:** Palo Alto, CA
- **Why they'd want PubMed full-text:** Multi-omics literature, systems biology research
- **Website:** https://genbio.ai

### 42. Absci Corporation
- **What they do:** Zero-shot AI antibody design without training data
- **Location:** Vancouver, WA
- **Why they'd want PubMed full-text:** Antibody engineering literature, protein expression research
- **Website:** https://absci.com

---

## Category 5: Emerging AI Biotechs

Newer companies building AI-first platforms for drug discovery.

### 43. Lila Sciences
- **What they do:** AI Science Factories for autonomous drug discovery; NVIDIA-backed
- **Location:** Boston, MA
- **Why they'd want PubMed full-text:** Automated literature mining for AI agents
- **Website:** https://lilasciences.com

### 44. AION Labs
- **What they do:** Israeli biotech venture studio creating AI-native drug discovery companies
- **Location:** Israel
- **Why they'd want PubMed full-text:** Literature-informed AI model training
- **Website:** https://aionlabs.com

### 45. ProteinQure
- **What they do:** Quantum computing + AI for peptide drug design
- **Location:** Toronto, Canada
- **Why they'd want PubMed full-text:** Peptide therapeutics literature, structural biology
- **Website:** https://proteinqure.com

### 46. Turbine
- **What they do:** Simulating cellular interactions for drug-resistant cancer therapeutics
- **Location:** Budapest, Hungary
- **Why they'd want PubMed full-text:** Cancer resistance literature, cell signaling research
- **Website:** https://turbine.ai

### 47. Cyclica
- **What they do:** Ligand Express platform for polypharmacology drug design
- **Location:** Toronto, Canada
- **Why they'd want PubMed full-text:** Drug-protein interaction literature, off-target research
- **Website:** https://cyclicarx.com

### 48. Healx
- **What they do:** AI for drug repurposing in rare diseases
- **Location:** Cambridge, UK
- **Why they'd want PubMed full-text:** Rare disease literature, drug repurposing research
- **Website:** https://healx.io
- **LinkedIn:** https://linkedin.com/company/healx

### 49. Polaris Quantum Biotech
- **What they do:** Quantum computing + AI for precision medicine drug design
- **Location:** Durham, NC
- **Why they'd want PubMed full-text:** Quantum chemistry literature, molecular design
- **Website:** https://polarisqb.com
- **LinkedIn:** https://linkedin.com/company/polarisqb

### 50. Engine Biosciences
- **What they do:** AI + genomics for genetic interaction discovery
- **Location:** Singapore
- **Why they'd want PubMed full-text:** Genetic interaction literature, synthetic lethality research
- **Website:** https://enginebio.com

---

## Category 6: Large Pharma with AI Divisions

Traditional pharma companies investing heavily in AI capabilities.

### 51. Roche (Genentech)
- **What they do:** 72 AI patents in Q1 2024 alone; digital pathology, predictive analytics
- **Location:** Basel, Switzerland / South San Francisco
- **Why they'd want PubMed full-text:** Enterprise-scale literature mining for R&D
- **Website:** https://roche.com

### 52. Bayer
- **What they do:** 44 AI patents in Q1 2024; ML for healthcare and agriculture
- **Location:** Leverkusen, Germany
- **Why they'd want PubMed full-text:** Cross-domain literature search (pharma + crop science)
- **Website:** https://bayer.com

### 53. Amgen
- **What they do:** 20 AI patents since 2020; biologics and biosimilars focus
- **Location:** Thousand Oaks, CA
- **Why they'd want PubMed full-text:** Biologics development literature
- **Website:** https://amgen.com

### 54. Takeda Pharmaceutical
- **What they do:** #1 in AI patent grants (18 since 2020); rare diseases focus
- **Location:** Tokyo, Japan / Cambridge, MA
- **Why they'd want PubMed full-text:** Rare disease research, mechanism literature
- **Website:** https://takeda.com

### 55. AstraZeneca
- **What they do:** 9 AI patents granted; oncology and immunology focus
- **Location:** Cambridge, UK
- **Why they'd want PubMed full-text:** Oncology literature, biomarker research
- **Website:** https://astrazeneca.com

### 56. Moderna
- **What they do:** IBM and OpenAI partnerships for mRNA science; AI for vaccine design
- **Location:** Cambridge, MA
- **Why they'd want PubMed full-text:** mRNA research literature, vaccine development
- **Website:** https://modernatx.com

### 57. Novartis
- **What they do:** $1B+ Generate Biomedicines partnership; AI in R&D
- **Location:** Basel, Switzerland
- **Why they'd want PubMed full-text:** Drug discovery literature at scale
- **Website:** https://novartis.com

### 58. Eli Lilly
- **What they do:** Isomorphic Labs partnership; insitro TuneLab collaboration
- **Location:** Indianapolis, IN
- **Why they'd want PubMed full-text:** Literature-powered AI model training
- **Website:** https://lilly.com

---

## Category 7: Additional High-Value Targets

### 59. ENSEM Therapeutics
- **What they do:** AI for difficult-to-drug oncology targets
- **Location:** Medford, MA
- **Why they'd want PubMed full-text:** Oncogene literature, target validation
- **Website:** https://ensemtx.com
- **LinkedIn:** https://linkedin.com/company/ensemtx

### 60. Treeline Biosciences
- **What they do:** Precision oncology with 3 Phase 1 programs; $1.1B funding
- **Location:** Watertown, MA
- **Why they'd want PubMed full-text:** Cancer target literature, clinical precedent
- **Website:** https://treeline.bio
- **LinkedIn:** https://linkedin.com/company/treeline-biosciences

### 61. Vesalius Therapeutics
- **What they do:** Understanding diseases driving 90% of human illness
- **Location:** Cambridge, MA
- **Why they'd want PubMed full-text:** Disease mechanism literature
- **Website:** https://vesaliustx.com
- **LinkedIn:** https://linkedin.com/company/vesaliustx

### 62. Zephyr AI
- **What they do:** Reshaping drug discovery and precision medicine approaches
- **Location:** Fairfax Station, VA
- **Why they'd want PubMed full-text:** Drug-disease relationship literature
- **Website:** https://zephyrai.bio
- **LinkedIn:** https://linkedin.com/company/zephyr-ai

### 63. Archetype Therapeutics
- **What they do:** AI-native computational drug discovery and repurposing
- **Location:** Winchester, MA
- **Why they'd want PubMed full-text:** Drug repurposing literature
- **Website:** https://archetypetx.com
- **LinkedIn:** https://linkedin.com/company/archetypetx

### 64. BioSymetrics
- **What they do:** Massive data analytics and prediction through pre-processing
- **Location:** New York, NY
- **Why they'd want PubMed full-text:** Biomedical data literature
- **Website:** https://biosymetrics.com
- **LinkedIn:** https://linkedin.com/company/biosymetrics

### 65. GNS Healthcare
- **What they do:** AI-powered causal machine learning for precision medicine
- **Location:** Cambridge, MA
- **Why they'd want PubMed full-text:** Causal biology literature, treatment response research
- **Website:** https://gnshealthcare.com

---

## Value Proposition Summary

### Why These Companies Need PubMed Full-Text Search:

1. **AI Model Training:** Full-text articles provide richer training data than abstracts alone
2. **Target Validation:** Methods sections contain experimental protocols for replication
3. **Mechanism Discovery:** Full papers explain biological pathways in detail
4. **Competitive Intelligence:** Complete literature review for IP and pipeline analysis
5. **Knowledge Graph Construction:** Full text enables entity extraction and relationship mapping
6. **Regulatory Submissions:** Complete literature reviews required for FDA filings
7. **Clinical Trial Design:** Historical data in full papers informs protocol development

### Key Selling Points:

- **Speed:** API access faster than manual PubMed searches
- **Completeness:** Full-text search catches information hidden in methods/results
- **Integration:** Direct integration with AI/ML pipelines
- **Scale:** Process millions of papers programmatically
- **Cost:** More affordable than licensing individual journals

---

## Outreach Strategy Notes

### Best Entry Points:
- VP/Director of Data Science
- Chief Scientific Officer
- Head of Computational Biology
- VP of R&D
- Director of AI/ML

### Timing Triggers:
- Recent funding rounds (need to scale capabilities)
- New pharma partnerships (need to deliver on commitments)
- Clinical trial initiation (need comprehensive lit reviews)
- Patent filings (need prior art searches)

### Competitor Landscape:
- Elsevier (expensive, limited API)
- Semantic Scholar (free but limited full-text)
- Europe PMC (good but primarily European focus)
- PubMed (no full-text API)

---

*Document maintained by Built Simple AI*
*For updates, contact the sales team*
